Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Evaluation of IL 12B Genetic Polymorphism (rs3213094)

Evaluation of IL 12B Genetic Polymorphism (rs3213094) in Patient With Psoriasis and Psoriatic Arthritis in Response to Humira

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Psoriasis is a skin disorder that is chronic proliferative and inflammatory in nature. Extensor surfaces, scalp, and lumbosacral area are covered in erythematous plaques with silvery scales. The disease can also impair the eyes and joints. It has no cure. Because of their low quality of life, many psoriasis patients experience depression. In addition to the cutaneous manifestations, it is associated with an increased risk of psoriatic arthritis, depression and cardiovascular disease.

Who May Be Eligible (Plain English)

Who May Qualify: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis. Who Should NOT Join This Trial: - Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus). - Pregnancy and lactation. - Patients currently undergoing any treatment other than Humira. - Patients with known genetic disorders affect immune system function. - Patients were undergoing any treatment other than Humira in the last 6 months. - Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV). - Patients with contraindication to Humira. - Renal \&Vascular diseases Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: \- Patients having psoriasis diagnosed clinically for at least 6 months and who have a severity grade of severe, defined as a Psoriasis Area and Severity Index (PASI) score greater than 10, and involvement of greater than 10% of the body surface area (BSA) with psoriatic arthritis. Exclusion Criteria: * Patients with other autoimmune or inflammatory conditions (e.g., rheumatoid arthritis, lupus). * Pregnancy and lactation. * Patients currently undergoing any treatment other than Humira. * Patients with known genetic disorders affect immune system function. * Patients were undergoing any treatment other than Humira in the last 6 months. * Patients with active infections, including tuberculosis or chronic viral infections (e.g., hepatitis B or C, HIV). * Patients with contraindication to Humira. * Renal \&Vascular diseases

Treatments Being Tested

DRUG

Humira

Assess the response of psoriasis and psoriatic arthritis to Humira and also Assessing the pharmacogenetic association between IL 12B genetic polymorphism (rs3213094) in psoriatic and psoriatic arthritis patients taking Humira.

Locations (1)

Qina University hospital, South Valley University Hospital
Qina, Egypt